company background image
TCRT logo

Alaunos Therapeutics NasdaqCM:TCRT Stock Report

Last Price

US$1.96

Market Cap

US$3.1m

7D

19.5%

1Y

-73.6%

Updated

23 Dec, 2024

Data

Company Financials

Alaunos Therapeutics, Inc.

NasdaqCM:TCRT Stock Report

Market Cap: US$3.1m

TCRT Stock Overview

A clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. More details

TCRT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 17.2% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($7K)

Does not have a meaningful market cap ($3M)

Highly volatile share price over the past 3 months compared to the US market


My Notes

Capture your thoughts, links and company narrative

Alaunos Therapeutics, Inc. Competitors

Biodexa Pharmaceuticals

NasdaqCM:BDRX

US$2.3m

Oragenics

NYSEAM:OGEN

US$4.3m

Aptorum Group

NasdaqCM:APM

US$4.0m

Quoin Pharmaceuticals

NasdaqCM:QNRX

US$2.9m

Price History & Performance

Summary of share price highs, lows and changes for Alaunos Therapeutics
Historical stock prices
Current Share PriceUS$1.96
52 Week HighUS$32.85
52 Week LowUS$1.63
Beta-0.44
1 Month Change-17.99%
3 Month Change-41.49%
1 Year Change-73.60%
3 Year Change-98.87%
5 Year Change-99.73%
Change since IPO-99.60%

Recent News & Updates

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

Shareholder Returns

TCRTUS BiotechsUS Market
7D19.5%-3.8%-2.7%
1Y-73.6%-2.6%23.4%

Return vs Industry: TCRT underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: TCRT underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is TCRT's price volatile compared to industry and market?
TCRT volatility
TCRT Average Weekly Movement17.4%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: TCRT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TCRT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20031Dale Hoguewww.alaunos.com

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.

Alaunos Therapeutics, Inc. Fundamentals Summary

How do Alaunos Therapeutics's earnings and revenue compare to its market cap?
TCRT fundamental statistics
Market capUS$3.14m
Earnings (TTM)-US$11.78m
Revenue (TTM)US$7.00k

448.4x

P/S Ratio

-0.3x

P/E Ratio

Is TCRT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TCRT income statement (TTM)
RevenueUS$7.00k
Cost of RevenueUS$1.38m
Gross Profit-US$1.37m
Other ExpensesUS$10.41m
Earnings-US$11.78m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-7.36
Gross Margin-19,628.57%
Net Profit Margin-168,285.71%
Debt/Equity Ratio0%

How did TCRT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alaunos Therapeutics, Inc. is covered by 22 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)
Vernon BernardinoBrinson Patrick Securities Corporation